Clinical trial · Interventional
A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
A Randomized, Controlled Multicenter Trial of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma
NCT01002092CI-TRIAL-00015529unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Purpose: This study will assess the safety and efficacy of Endostar combined with chemotherapy in osteosarcoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Endostar | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Chemotherapy
- interventionNames
- Drug: Chemotherapy
- type
- EXPERIMENTAL
- label
- Endostar plus Chemotherapy
- interventionNames
- Drug: Chemotherapy
- Drug: Endostar
Primary outcomes (1)
- measure
- Progression Free Survival
- timeFrame
- 5 years
Secondary outcomes (5)
- measure
- Limb Salvage Rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed osteosarcoma, who have no evidence of metastasis * At least one measurable lesion * Life expectancy \> 3 months * ECOG performance status 0-2 * Adequate hematologic, cardiac, renal, and hepatic function * Patients with prior chemotherapy should have at least 4 weeks clearance period before entering this study Exclusion Criteria: * Evidence of metastasis * Serious infection * Evidence of bleeding diathesis * Significant cardiovascular disease * Pregnant or lactating woman * Allergic to E.coli preparation
References
Publications (0)
Data not yet available
No reference posted for this study.